Stereotaxis launches Stereotaxis Epoch solution for electrophysiology lab

Apr 27 2011

Stereotaxis, Inc. (Nasdaq: STXS) today announces the introduction of its new Stereotaxis Epoch™  platform, a comprehensive solution for any electrophysiology lab which combines the recognized benefits of remote magnetic catheter control, the efficiency of remote robotic device manipulation, and the power of the Odyssey platform, enabling highly sophisticated procedural data integration and transmission. The Epoch™ platform will be unveiled at the annual Heart Rhythm Society meeting May 5-7, 2011 in San Francisco, CA.

The Stereotaxis Epoch solution is the beginning of a new modular platform designed to meet the broad range of clinical needs physicians face today and in the future. Building on the strength of Magnetic Navigation's exceptional safety profile and significant radiation reduction, the Epoch platform features the latest technological breakthroughs in Magnetic Navigation, which will lead to faster, more efficient, and dynamic magnetic catheter control. In addition, the Epoch platform will seamlessly integrate Stereotaxis' Vdrive™ mechanical robotic platform for remote manipulation of a growing array of devices, such as loop diagnostic catheter and sheath.  

The Epoch solution delivers value well beyond the lab with the power of Stereotaxis' Odyssey™ solution–an unprecedented offering which integrates the complex array of clinical data into synchronized, high-definition view delivering real-time clinical information anywhere at physicians' fingertips. The Odyssey solution empowers hospital executives to drive initiatives which improve care, enhance performance, and increase referrals and market services throughout global communities.    

"We are excited to introduce our Epoch solutions to the EP market as we are committed to developing solutions that meet the most critical needs of our customers, while supporting any preferred clinical treatment technique," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. "Early feedback from key opinion leaders suggests that the Epoch platform enables us to deliver a much more efficient and enhanced EP workflow while maintaining our excellent profile in safety, radiation reduction and clinical outcome."

Stereotaxis expects that the Stereotaxis Epoch solutions will significantly reduce procedure time for all types of robotic-assisted EP procedures, especially for atrial fibrillation ablation procedures. In addition, user learning curve will be accelerated as a result of automated scripting of expert users' navigation techniques. Furthermore, labs equipped with the Vdrive module can benefit from optimized and full remote navigation and control of devices such as loop diagnostic catheters and sheaths.

While customers in EU markets already have commercial access to the Vdrive module, Vdrive is currently under FDA 510(k) review prior to its commercial availability in the U.S. market.  

SOURCE Stereotaxis, Inc.